Abstract:Background: The hallmarks of hepatic ischemia/reperfusion (I/R) injury, a common clinical problem that occurs during liver surgical procedures, include severe cell death and inflammatory responses that contribute to early graft failure and a higher incidence of organ rejection. Unfortunately, effective therapeutic strategies are limited. β-arrestins are multifunctional proteins that mediate receptor desensitization and serve as important signaling scaffolds in numerous physiopathological processes. However, the role of β-arrestins in hepatic I/R remains largely unknow. Methods: We overexpressed Arrb1 in the hepatocyte of C57BL/6 mice using an Arrb1 adeno-associated virus. Wide-type, Arrb1 overexpressing and knockout mice were subjected to a partial (70%) hepatic ischemia for 60 minutes, followed by various periods of reperfusion. Isolated hepatocytes from different group of mice were subjected to hypoxia-reoxygenation (H/R) injury to determine the in vitro effects of Arrb1. The molecular mechanisms underlying Arrb1-regulatd hepatic I/R injury were further explored and verified in mice. Findings: Here, we showed that only Arrb1 was downregulated during I/R-injured liver injury. Hepatocyte-specific overexpression of Arrb1 significantly ameliorated liver damage, as demonstrated by decreases in serum aminotransferases, hepatocellular necrosis and apoptosis, infiltrating inflammatory cells and secretion of pro-inflammatory cytokines relative to control mice. Whereas, experiments with Arrb1 knockout mice reveled opposite effects. Mechanistically, Arrb1 directly interacts with TRAF6 in hepatocyte, and inhibits the ubiquitination of TRAF6, which then prevents the activation of the downstream MAPK and NF-κB signaling pathways during hepatic I/R injury. Interpretation: The Arrb1-TRAF6 interaction inhibited the ubiquitination of TRAF6 and the activation of MAPK and NF-κB signaling, and then protected against cell death and inflammation, suggesting Arrb1 is a potential therapeutic target for hepatic I/R injury. Funding: This research was supported by grants from the 481 National Key Research and Development Program of China (2016YFC0905900), The State Key Program of National Natural Science Foundation of China (81430062), and the Innovative Research Groups of the National Natural Science Foundation (81521004 to B.S.). The authors declare no conflicts of interest. Declaration of Interest: The authors declare no potential conflicts of interest. Ethical Approval: Animal protocols were approved by the Animal Care and Use Committee of Nanjing Medical University, and experiments were conducted in adherence with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, Bethesda, MD, USA). We gained permission from all the patients and healthy volunteers, and the procedures of our study on the basis of the basic principles of Helsinki Declaration were approved by the Ethics Committee of Nanjing Drum Tower Hospital.

JuA alleviates liver ischemia-reperfusion injury by activating AKT/NRF2/HO-1 pathways

Hongjingtian Injection Attenuates Myocardial Oxidative Damage Via Promoting Autophagy and Inhibiting Apoptosis.

Jujuboside A Ameliorates Myocardial Apoptosis and Inflammation in Rats with Coronary Heart Disease by Inhibiting PPAR-α Signaling Pathway

15-Deoxy-Δ12,14-prostaglandin J2 alleviates hepatic ischemia-reperfusion injury in mice via inducing antioxidant response and inhibiting apoptosis and autophagy

Aucubin Attenuates Liver Ischemia-Reperfusion Injury by Inhibiting the HMGB1/TLR-4/NF-κB Signaling Pathway, Oxidative Stress, and Apoptosis

KEAP1-NRF2 Complex in Ischemia-Induced Hepatocellular Damage of Mouse Liver Transplants

Activation of Cyclic Adenosine Monophosphate-Dependent Protein Kinase a Signaling Prevents Liver Ischemia/reperfusion Injury in Mice

Jujuboside A inhibits oxidative stress damage and enhances immunomodulatory capacity of human umbilical cord mesenchymal stem cells through up-regulating IDO expression

Bracteanolide A abrogates oxidative stress‐induced cellular damage and protects against hepatic ischemia and reperfusion injury in rats

Arrb1 Ameliorates Liver Ischemia/Reperfusion Injury Via Interacting with TRAF6 in Hepatocytes

Activation of APE1 modulates Nrf2 protected against acute liver injury by inhibit hepatocyte ferroptosis and promote hepatocyte autophagy

Apolipoprotein A-1 protected hepatic ischaemia-reperfusion injury through suppressing macrophage pyroptosis via TLR4-NF-κB pathway

Aloperine Attenuates Hepatic Ischemia/Reperfusion-Induced Liver Injury via STAT-3 Signaling in a Murine Model

Aucubin protects against myocardial ischemia-reperfusion injury by regulating STAT3/NF-κB/HMGB-1 pathway

Pretreatment with the ALDH2 activator Alda‐1 protects rat livers from ischemia/reperfusion injury by inducing autophagy

DHA attenuates hepatic ischemia reperfusion injury by inhibiting pyroptosis and activating PI3K/Akt pathway

Luteolin Pretreatment Attenuates Hepatic Ischemia-Reperfusion Injury in Mice by Inhibiting Inflammation, Autophagy, and Apoptosis via the ERK/PPARα Pathway

Crocetin preconditioning attenuates ischemia reperfusion-induced hepatic injury by disrupting Keap1/Nrf2 interaction and activating Nrf2/HO-1 pathway

Augmenter of Liver Regeneration Ameliorates Ischemia-Reperfusion Injury in Steatotic Liver Via Inhibition of the TLR4/NF-κB Pathway.

Protective effect of hydroxysafflor yellow A on renal ischemia‑reperfusion injury by targeting the Akt‑Nrf2 axis in mice

Activation of the PPARγ/NF-κB pathway by A-MPDA@Fe3O4@PVP via scavenging reactive oxygen species to alleviate hepatic ischemia-reperfusion injury